A new method used to treat asthma

A new study published in the Journal of Allergy and Clinical Immunology investigates a potential new approach for the treatment of asthma. According to research using recombinant human proteins, asthma causes the individual's airway to become inflamed and narrower and produce additional mucus. The patient's breathing becomes difficult, and the result is a wheezing and coughing. It is estimated that 12% of people in the United States suffer from asthma, equivalent to about 25 million people.

There is a series of potential triggers for asthma. These include pollen, mold, dust mite, animal dander, air pollution, certain medications and exercise. The current drugs can effectively treat many people's symptoms, but as the lead author of the study, Dr. Ruth Sander said, "For many people with asthma, especially severe asthma, treatment is not 100% effective. Although the study is aimed at new treatments for allergic-related asthma, it still requires new therapies for allergies that are independent of allergies, and the steady increase in asthma cases and their fatalities and the shortage of drugs in some individuals make asthma research an important area of research."

A recent study at the University of Leicester, UK, investigated the role of specific proteins in asthma, called the high mobility group box 1 (HMGB1). Researchers hope their findings may pave the way for more effective treatment. HMGB1 is a chromatin protein, meaning that it helps to tissue DNA and regulate its transcription in the nucleus. It is secreted by immune cells (including monocytes, macrophages and dendritic cells) and promotes inflammatory responses.

Current studies use mucus and muscle tissue from mild to moderate patients with asthma. It is known that the smooth muscle in the airway has a significant contribution to the symptoms of asthma; it is overly contracted and the quality is increased, and the chemicals involved in the inflammatory response are released. "As far as we know, this is the first study to show that HMGB1 has a direct effect on stimulating the increased airway muscle contraction, and this study has led us closer to improving the treatment of patients with severe asthma," Dr. Sanders continued.

This is the early stage of the study of this new approach. However, it marks an important leap; by understanding the role of HMGB1 and its role in asthma, eventually we can take new interventions. By the way, Flarebio provides you with high-quality recombinant proteins like recombinant ECEL1 at competitive prices.